Advancing Pediatric Drug Safety: The Potential of Physiologically Based Pharmacokinetic Modeling

Physiologically Based Pharmacokinetic (PBPK) modeling represents an advanced computational model that bridges the gap between theoretical pharmacology and clinical practice. These advanced mathematical frameworks integrate complex physiological parameters with absorption, distribution, metabolism, and excretion (ADME) processes to create dynamic simulations of drug behavior in biological systems. By providing mechanistic insights into drug disposition and interactions, PBPK models have become indispensable tools in modern drug development and clinical therapeutics. The evolution of PBPK modeling has particularly revolutionized pediatric pharmacology, where traditional dosing paradigms often fall short due to the unique physiological characteristics of developing organisms. These models excel in their ability to predict pharmacokinetic profiles across diverse age groups, offering crucial insights into the fundamental differences between adult and pediatric drug handling. Their capability to anticipate drug-drug interactions (DDIs) has proven especially valuable in pediatric settings, where complex medication regimens are increasingly common. The growing adoption of PBPK modeling by pharmaceutical companies, regulatory agencies, and clinical institutions underscores its pivotal role in contemporary drug development. These models demonstrate remarkable effectiveness in translating adult pharmacokinetic data to pediatric populations, integrating multiple evidence streams to elucidate age-specific differences in drug disposition. This translational capacity has become particularly crucial in optimizing pediatric drug development strategies and enhancing therapeutic decision-making. This article presents a comprehensive analysis of PBPK modeling, examining its foundational principles and recent advances in adult-to-pediatric pharmacokinetic translation. Special attention is devoted to the unique challenges and emerging solutions in pediatric PBPK (P-PBPK) modeling, particularly in the context of DDIs. Through detailed exploration of these aspects, we illuminate how PBPK modeling continues to advance our understanding of drug behavior in pediatric patients, ultimately contributing to more precise and safer therapeutic interventions for this vulnerable population.